Official data from a study published in the UK on the 10th showed that a single dose of the Oxford/Astedilicon (AZ) vaccine reduced the risk of death from Wuhan pneumonia (novel coronavirus disease, COVID-19) by 80%. Public Health England highlights that this is the first study based on real-world data on the effectiveness of the AZ vaccine in preventing death.
With more than 2/3 of the adult population in the UK having received at least one dose of the vaccine to date, the epidemic has been slowing down recently, with only two deaths in the past 28 days and zero deaths in England, Scotland and Northern Ireland on the 9th. The last time England had zero deaths in a single day was last summer. Prime Minister Johnson therefore announced that England will further relax the closure order next week to allow restaurants and bars to open indoors.
Reuters reports that the aforementioned study looked at vaccination status by looking at new cases of martial lung between December last year and April this year and those who died within 28 days of a positive test. The results showed that compared to those who were not vaccinated, those who had one dose of AZ vaccine were 55% more effective in preventing death, and those who had one dose of Pfizer vaccine were 44% more effective.
A Public Health England statement said, “Together with the protection offered by the vaccine against confirmation from the outset, this is equivalent to one dose of either of the two vaccines preventing about 80 percent of deaths.”
According to the study, the Pfizer vaccine boosted protection to 97 percent after two doses. The U.S. Food and Drug Administration (FDA) authorized the Pfizer vaccine to be administered to adolescents between the ages of 12 and 15 on Oct. 10, which is seen as an important step in getting children back to school safely, and President Joe Biden asked states to give these adolescents immediate access to the vaccine.
Another study published last month by Oxford University showed that a single dose of AZ or Pfizer vaccine could reduce the rate of martial lung infections by 65 percent under realistic conditions, and that the protective power of a single dose of the vaccine was consistent across age groups.
The team also analyzed the antibody response produced by the vaccine and found that antibodies rose faster and in higher concentrations after a single dose of Pfizer vaccine, but then declined to levels similar to those of the AZ vaccine, especially in older adults. Although the immune response varied, the researchers noted that 95% of those vaccinated had a robust antibody response.